Ayushman Bharat's expanding health-data infrastructure could help Indian pharmaceutical researchers evaluate treatment outcomes, strengthen drug safety monitoring and improve real-world evidence.
Cipla’s Rs 423 crore R&D investment signals a long-term growth bet despite a 35% profit decline and weaker US sales.
TROP2 ADC sac-TMT extends survival in advanced endometrial cancer, offering a potential new treatment option after chemotherapy and immunotherapy failure in a late-stage clinical trial.
Eris Lifesciences targets semaglutide market expansion to Rs 80-90 crore monthly by next year, driven by rising demand for diabetes therapies.
GSK and Hansoh's Ris-Rez shows promise in osteosarcoma treatment, reducing progression risk in a Phase III trial and highlighting unmet needs after relapse.
Haryana ends OPD queue hardship with UPI payments and home registration, making public hospital visits faster, simpler and more convenient.
Biocon’s Yesintek gains market entry into nine high-growth markets, expanding its global biosimilar reach through a settlement with Janssen Sciences Ireland.
AIG Hospitals and Boston Scientific are expanding specialist training to support access to advanced gastrointestinal procedures beyond major Indian cities.
A KGMU report highlights gaps in breast cancer screening follow-up in Uttar Pradesh, raising concerns about timely diagnosis and access to care.
India has come a long way in the management of cardiovascular disease. With advances in diagnostics, interventional cardiology and cardiac surgery, patients with complex heart conditions have more options than ever before. However, access to newer su
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")
